Table 4. Prevalence of Catecholaminergic Genotypes in IBS Patients and Healthy Controls.

SNP (Gene)	Healthy Controls				IBS Patients
rs1556832 (ADRA1D)	C/C	C/T	T/T	No Call	C/C	C/T	T/T	No Call
	166 (43.6%)	159 (41.7%)	51 (13.4%)	5 (1.3%)	93 (33.5%)	134 (48.2%)	47 (16.9%)	4 (1.4%)
rs946188 (ADRA1D)	A/A	A/G	G/G	No Call	A/A	A/G	G/G	No Call
	191 (50.1%)	162 (42.5%)	20 (5.2%)	8 (2.1%)	140 (50.4%)	118 (42.4%)	11 (4%)	9 (3.2%)
rs1432622 (ADRAβ2)	C/C	C/T	T/T	No Call	C/C	C/T	T/T	No Call
	164 (43%)	161 (42.3%)	50 (13.1%)	6 (1.6%)	106 (38.1%)	128 (46%)	40 (14.4%)	4 (1.4%)
rs2400707 (ADRAβ2)	G/G	A/G	A/A	No Call	G/G	A/G	A/A	No Call
	164 (43%)	161 (42.3%)	51 (13.4%)	5 (1.3%)	106 (38.1%)	129 (46.4%)	41 (14.7%)	2 (0.7%)
rs1042717 (ADRAβ2)	G/G	A/G	A/A	No Call	G/G	A/G	A/A	No Call
	164 (43%)	161 (42.3%)	51 (13.4%)	5 (1.3%)	106 (38.1%)	129 (46.4%)	41 (14.7%)	2 (0.7%)
rs1042713 (ADRAβ2)	G/G	A/G	A/A	No Call	G/G	A/G	A/A	No Call
	120 (31.5%)	165 (43.3%)	84 (22%)	12 (3.1%)	95 (34.2%)	123 (44.2%)	47 (16.9%)	13 (4.7%)
rs1800497 (ANKK1)	C/C	C/T	T/T	No Call	C/C	C/T	T/T	No Call
	192 (50.4%)	148 (38.8%)	36 (9.4%)	5 (1.3%)	159 (57.2%)	93 (33.5%)	24 (8.6%)	2 (0.7%)
rs6269 (COMT)	A/A	A/G	G/G	No Call	A/A	A/G	G/G	No Call
	171 (44.9%)	158 (41.5%)	46 (12.1%)	6 (1.6%)	107 (38.5%)	129 (46.4%)	38 (13.7%)	4 (1.4%)
rs4680 (COMT)	G/G	A/G	A/A	No Call	G/G	A/G	A/A	No Call
	128 (33.6%)	181 (47.5%)	68 (17.8%)	4 (1%)	98 (35.3%)	111 (39.9%)	59 (21.2%)	10 (3.6%)
rs174697 (COMT)	G/G	A/G	A/A	No Call	G/G	A/G	A/A	No Call
	250 (65.6%)	107 (28.1%)	19 (5%)	5 (1.3%)	219 (78.8%)	52 (18.7%)	6 (2.2%)	1 (0.4%)
rs6280 (DRD3)	T/T	C/T	C/C	No Call	T/T	C/T	C/C	No Call
	142 (37.3%)	169 (44.4%)	66 (17.3%)	4 (1%)	107 (38.5%)	123 (44.2%)	44 (15.8%)	4 (1.4%)